A team of medical researchers is testing a new type of “electricity-based” treatment for mesothelioma – refers it to as the “most promising therapeutic alternative.” The final results of phase II clinical trial have been released recently.
Tumor Treating Fields –a venture of the Jersey-based Novocure, has been alternating the electric fields that help in destabilizing the critical proteins of the body and thus, helps in disrupting the process of cell division in the mesothelioma tumor, and eventually kills them. The early tests of the given test appear promising. However, the final results of the Stellar Phase II clinical trial that were released later this week were even better.
The team of researchers says that the Tumor Treating Fields could go forward with becoming a major part of the new medical standards of taking care of the pleural mesothelioma.
The revolutionary Tumor Treating Fields initially found success during the treatment of the fatal brain cancer –glioblastoma. In the year 2016, Novocure shifted its attention to coming up with the treatment for pleural mesothelioma –another rare type of cancer that usually carries along a poor prognosis.
On the basis of the initial results of the tests that have shown a significant increase in the overall mesothelioma survival with the help of Tumor Treating Fields, the device went forward with receiving the Humanitarian Use designation from the United States Food & Drug Administration (FDA) in the year 2017. The final results of the tests have confirmed the overall value of the Tumor Treating Fields device –especially in connection with